Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
(3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester is a specialized chiral building block widely utilized in the field of organic synthesis and pharmaceutical research. With the molecular formula C₁₆H₂₀BrNO₃ and a molecular weight of approximately 358.24 g/mol, this compound features a pyrrolidine core substituted with a bromoacetyl group at the third position and an ethyl group at the fourth position, all protected by a benzyl ester moiety. The specific stereochemistry denoted as (3R,4S) is critical for its application in asymmetric synthesis, ensuring high enantiomeric purity required for bioactive molecule construction. Although a specific CAS registry number is not universally standardized under a single public database entry due to its status as a custom synthetic intermediate, it is frequently cataloged by major chemical suppliers for research purposes.
The primary utility of this molecule lies in its role as a precursor for the development of complex heterocyclic compounds and potential drug candidates. The presence of the reactive bromoacetyl group makes it an excellent electrophile for nucleophilic substitution reactions, allowing chemists to introduce various amine or thiol functionalities efficiently. Simultaneously, the benzyl ester serves as a robust protecting group that can be selectively removed under mild hydrogenation conditions without affecting other sensitive functional groups within the molecule. This dual reactivity profile facilitates the stepwise assembly of intricate molecular architectures common in medicinal chemistry. Researchers often employ this intermediate in the synthesis of peptidomimetics, enzyme inhibitors, and novel alkaloids where precise stereocontrol dictates biological activity. Its stability under standard storage conditions and solubility in common organic solvents like dichloromethane, tetrahydrofuran, and ethyl acetate further enhance its practicality in laboratory settings. Consequently, (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester remains a valuable asset for academic institutions and pharmaceutical companies dedicated to advancing therapeutic agents through rational design and rigorous synthetic methodologies.